PTC Therapeutics, a US-based drugs developer for muscles, raises $144.4m on Nasdaq.
PTC Therapeutics, a US-based drugs developer for muscles, closed its initial public offering (IPO) on June 25, 2013, selling 9.6 million shares (including 1.3 million purchased by the underwriters) priced at $15 per share, for a total of $144.4 million. After underwriting discounts and commissions of $1.05 per share, PTC’s shares were priced at $13.95, raising $134.3m for the company.
PTC had planned to offer 6.9 million shares at between $13 and $16 each. In first day trading, PTC’s share…
